Celcuity Inc. (CELC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Celcuity Inc. (CELC) Healthcare & Pipeline Overview

Celcuity Inc. is a clinical-stage biotechnology firm leveraging its CELsignia diagnostic platform to develop targeted cancer therapies. The company focuses on identifying abnormal cellular processes in tumors to personalize treatment, primarily targeting hormone receptor-positive, HER2-negative breast cancer. It operates within the competitive biotechnology landscape, holding a license agreement with Pfizer for Gedatolisib.

What Is the Investment Thesis for CELC?

Celcuity's investment thesis rests on the potential of its CELsignia diagnostic platform to personalize cancer treatment and improve patient outcomes. The company's focus on targeted therapies, particularly Gedatolisib for hormone receptor-positive, HER2-negative breast cancer, addresses a significant unmet need. Key value drivers include successful clinical trial results for Gedatolisib and the expansion of the CELsignia platform to other cancer types. Upcoming clinical trial data releases will serve as catalysts. A potential risk involves clinical trial setbacks or regulatory hurdles. With a market cap of $4.17B and a beta of 0.42, Celcuity presents a moderately volatile investment opportunity within the biotechnology sector.

Based on FMP financials and quantitative analysis

CELC Key Highlights

Celcuity's focus on personalized medicine through its CELsignia diagnostic platform positions it at the forefront of targeted cancer therapy.

• Gedatolisib, Celcuity's lead drug candidate, targets key signaling pathways (PI3K and mTOR) involved in cancer growth, offering a potential treatment for hormone receptor-positive, HER2-negative breast cancer.
• The CELsignia MP test aims to refine patient selection for targeted therapies by measuring HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.
• Celcuity's previous license agreement with Pfizer for Gedatolisib validates the potential of its technology and drug candidates.
• With 87 employees, Celcuity maintains a focused and agile approach to drug development and diagnostic innovation.

Who Are CELC's Competitors?

CELC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CELC's Key Strengths?

Proprietary CELsignia diagnostic platform.

• Targeted therapies address unmet needs in cancer treatment.
• Experienced management team with expertise in drug development.
• Strategic partnerships with pharmaceutical companies.

What Are CELC's Weaknesses?

Clinical-stage company with no currently marketed products.

• High R&D costs and long development timelines.
• Reliance on successful clinical trial outcomes.
• Competition from larger pharmaceutical companies.

What Could Drive CELC Stock Higher?

Data readout from ongoing clinical trials of Gedatolisib in hormone receptor-positive, HER2-negative breast cancer.

• Potential regulatory submissions for Gedatolisib based on clinical trial results.
• Expansion of the CELsignia platform to new cancer types.
• Strategic partnerships and collaborations with pharmaceutical companies.

What Are the Key Risks for CELC?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Insider selling — insiders were net sellers of roughly $322.9M recently.
• Clinical trial failures or delays for Gedatolisib.
• Regulatory hurdles and approval delays for Gedatolisib.
• Competition from other cancer therapies.
• Patent challenges and intellectual property disputes.
• Dependence on key personnel and strategic partnerships.

What Are the Growth Opportunities for CELC?

• Expansion into New Therapeutic Areas: Celcuity has the opportunity to expand the application of its CELsignia platform to other cancer types beyond breast and ovarian cancer. This could involve developing new diagnostic tests and targeted therapies for lung cancer, colorectal cancer, and other prevalent malignancies. The global market for cancer therapeutics is projected to reach $286 billion by 2028, providing a substantial growth opportunity for Celcuity. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Celcuity can pursue strategic partnerships with pharmaceutical companies and research institutions to accelerate the development and commercialization of its products. Collaborations could involve co-development of new therapies, licensing agreements, or joint research programs. Such partnerships can provide Celcuity with access to additional funding, expertise, and market reach. Timeline: Ongoing.
• Commercialization of CELsignia MP Test: The successful commercialization of the CELsignia MP test represents a significant growth opportunity for Celcuity. This test can be used to guide treatment decisions for patients with breast and ovarian cancer, potentially improving outcomes and reducing healthcare costs. The market for diagnostic tests in oncology is expected to grow significantly in the coming years. Timeline: Upcoming.
• Advancement of Gedatolisib Through Clinical Trials: The continued advancement of Gedatolisib through clinical trials is crucial for Celcuity's growth. Positive clinical trial results could lead to regulatory approval and commercial launch, generating substantial revenue for the company. The market for PI3K inhibitors in cancer therapy is expected to grow as more targeted therapies are developed. Timeline: Ongoing.
• Geographic Expansion: Celcuity can expand its operations beyond the United States to international markets, such as Europe and Asia. This would involve establishing partnerships with local distributors and regulatory agencies. The global market for cancer therapeutics is growing rapidly, particularly in emerging economies. Timeline: Potential.

What Are CELC's Competitive Advantages?

• Proprietary CELsignia diagnostic platform provides a competitive advantage in personalized cancer treatment.
• Strong intellectual property portfolio protects its technologies and drug candidates.
• Expertise in molecularly targeted therapies and cancer biology.
• Strategic partnerships with pharmaceutical companies and research institutions.

What Does CELC Do?

Founded in 2011 and headquartered in Minneapolis, Minnesota, Celcuity Inc. is a clinical-stage biotechnology company dedicated to revolutionizing cancer treatment through personalized medicine. The company's core innovation is the CELsignia diagnostic platform, which analyzes living tumor cells to pinpoint the specific abnormal cellular processes driving a patient's cancer. This information is then used to identify the most effective targeted therapy for that individual. Celcuity's lead drug candidate, Gedatolisib, selectively targets various class I isoforms of PI3K and mammalian target of rapamycin (mTOR), key signaling pathways involved in cancer growth and progression. The company is focusing Gedatolisib's development on patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. In addition to Gedatolisib, Celcuity is developing the CELsignia MP test, a qualitative laboratory-developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. This test is designed to further refine patient selection for targeted therapies. Celcuity previously had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib, highlighting the potential of its technology and drug candidates.

What Products and Services Does CELC Offer?

• Develops molecularly targeted therapies for cancer patients.
• Utilizes the CELsignia diagnostic platform to identify abnormal cellular processes in tumors.
• Focuses on personalizing cancer treatment by matching patients with the most effective targeted therapies.
• Develops Gedatolisib, a drug candidate targeting PI3K and mTOR pathways.
• Conducts clinical trials to evaluate the safety and efficacy of Gedatolisib.
• Develops the CELsignia MP test to measure HER2, c-Met, and PI3K signaling activity in tumor cells.

How Does CELC Make Money?

• Develops and commercializes diagnostic tests and targeted therapies for cancer.
• Generates revenue through the sale of diagnostic tests and pharmaceuticals.
• Out-licenses its technologies and drug candidates to pharmaceutical companies.
• Receives milestone payments and royalties from licensing agreements.

What Industry Does CELC Operate In?

Celcuity operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market for targeted cancer therapies is experiencing significant growth, driven by advancements in genomics and personalized medicine. Celcuity's CELsignia platform aligns with this trend by enabling the selection of patients most likely to respond to specific therapies. Competitors like CG Oncology Inc and Legend Biotech Corporation are also developing innovative cancer treatments, highlighting the competitive landscape. The biotechnology industry is expected to continue growing, fueled by increasing cancer incidence and the demand for more effective and personalized treatments.

Who Are CELC's Key Customers?

• Cancer patients seeking personalized treatment options.
• Oncologists and other healthcare professionals who treat cancer patients.
• Pharmaceutical companies that license Celcuity's technologies and drug candidates.
• Research institutions that collaborate with Celcuity on drug development.

Celcuity Inc. Financial Trajectory

Celcuity Inc. (CELC) reported $0 in revenue for Jun 2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $78.9M, with diluted EPS of $-1.44. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, CELC averaged $-1.09 in diluted EPS.

Company Profile

Celcuity Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Brian F. Sullivan. CELC has traded publicly since 2017.

How Celcuity Inc. Is Valued

Celcuity Inc. carries a market capitalization of $4.17B, placing it in the mid-cap category. Analyst price targets span from $110.00 to $178.00, with a consensus of $154.33. At the current price of $85.49, that implies approximately 81% upside potential. Relative to its peer group, CELC's quantitative score of 51/100 is below the peer average of 62/100.

Key Financial Metrics

Return on assets is -47.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.

Celcuity Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.41 places it in the grey zone, a middle ground that warrants monitoring.

Celcuity Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.9% below estimates on average.

Wall Street analysts project Celcuity Inc. revenue of about $38.2M for fiscal 2026, with EPS near $-4.85. The estimate reflects 7 contributing analysts.

Over the past six months, Celcuity Inc. insiders filed 36 SEC Form 4 transactions — 18 sales and 18 purchases. On net that is roughly 2.9M shares disposed (about $322.9M), a signal worth weighing alongside the fundamentals.

CELC Financials

CELC Latest News

CELC Analyst Consensus

CELC MoonshotScore

What Investors Ask About Celcuity Inc. (CELC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources